a Department of Food Science and Biotechnology , Kangwon National University , Chuncheon , South Korea.
b Department of Microbiology/Immunology , McGill University , Montreal , QC , H3A 2B4 , Canada.
Crit Rev Food Sci Nutr. 2018;58(13):2273-2284. doi: 10.1080/10408398.2017.1319795. Epub 2017 Sep 29.
The remarkable growth of therapeutic peptide development in the past decade has led to a large number of market approvals and the market value is expected to hit $25 billion by 2018. This significant market increase is driven by the increasing incidences of metabolic and cardiovascular diseases and technological advancements in peptide synthesis. For this reason, the search for bioactive peptides has also increased exponentially. Many bioactive peptides from food and nonfood sources have shown positive health effects yet, obstacles such as the need to implement efficient and cost-effective strategies for industrial scale production, good manufacturing practices as well as well-designed clinical trials to provide robust evidence for supporting health claims continue to exist. Several other factors such as the possibility of allergenicity, toxicity and the stability of biological functions of the peptides during gastrointestinal digestion would need to be addressed.
在过去十年中,治疗性肽的开发取得了显著的增长,已获得大量的市场批准,预计到 2018 年市场价值将达到 250 亿美元。这种显著的市场增长是由代谢和心血管疾病发病率的增加以及肽合成技术的进步所驱动的。出于这个原因,对生物活性肽的搜索也呈指数级增长。许多来自食物和非食物来源的生物活性肽已经显示出了积极的健康影响,但仍存在一些障碍,如需要实施高效和具有成本效益的策略来实现工业规模生产、良好的生产规范以及精心设计的临床试验,以提供支持健康声称的有力证据。还需要解决其他一些因素,如肽在胃肠道消化过程中产生过敏、毒性和生物功能稳定性的可能性。